News
HBIO
5.25
-4.89%
-0.27
Weekly Report: what happened at HBIO last week (0511-0515)?
Weekly Report · 34m ago
Harvard Bioscience Earnings Call Highlights Gradual Recovery
TipRanks · 5d ago
Harvard Bioscience reports Q1 adjusted EPS (33c) vs. ($1.25) last year
TipRanks · 5d ago
Harvard Bioscience reiterates Q2 revenue view $20.5M-$22.5M
TipRanks · 5d ago
Harvard Bioscience reaffirms FY26 revenue growth of 2%-4%
TipRanks · 5d ago
Harvard Bioscience reaffirms 2026 outlook for 2%-4% revenue growth as Project Viking targets $4M annual savings
Seeking Alpha · 5d ago
Harvard Bioscience Unveils Strategic Transformation Toward Translational Tools
TipRanks · 5d ago
Harvard Bioscience Q1 2026 Earnings Call Transcript
Benzinga · 5d ago
Harvard Bioscience Q1 revenue falls, reaffirms 2026 guidance
Reuters · 5d ago
Harvard Bioscience misses top-line and bottom-line estimates; initiates Q2 and reaffirms FY26 outlook
Seeking Alpha · 5d ago
Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est
Benzinga · 5d ago
Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate
Benzinga · 5d ago
*Harvard Bioscience Still Sees 2026 Adjusted Ebitda Up 6%-10% >HBIO
Dow Jones · 5d ago
*Harvard Bioscience Sees 2Q Adjusted Ebitda $1M-$2M >HBIO
Dow Jones · 5d ago
*Harvard Bioscience Still Sees 2026 Revenue Up 2%-4% >HBIO
Dow Jones · 5d ago
*Harvard Bioscience Sees 2Q Rev $20.5M-$22.5M >HBIO
Dow Jones · 5d ago
*Harvard Bioscience Reaffirms Full-Year 2026 Financial Guidance >HBIO
Dow Jones · 5d ago
*Harvard Bioscience: Consolidation of Manufacturing Operations Progressing on Schedule >HBIO
Dow Jones · 5d ago
HARVARD BIOSCIENCE ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS
Reuters · 5d ago
Press Release: Harvard Bioscience Announces First -3-
Dow Jones · 5d ago
More
Webull provides a variety of real-time HBIO stock news. You can receive the latest news about Harvard Biosci through multiple platforms. This information may help you make smarter investment decisions.
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.